GlaxoSmithKline will pay $ 3 billion record fine
GSK (GlaxoSmithKline) has agreed to pay a record fine of $ 3 billion to settle U.S. drug regulatory agencies of its allegations. U.S. drug regulators said GlaxoSmithKline unscrupulous marketing, sell some drugs to ignore their authorized purposes, a certain selectivity of clinical trial data to be used (such as an antidepressant, GlaxoSmithKline The sales representative is referred to as “happy, mighty slim pill”).
As part of the settlement agreement, the British pharmaceutical company to accept its criminal charges by the regulatory bodies. The case is considered to be the U.S. medical field with fraud.
GlaxoSmithKline last provision of £ 2.2 billion used to pay the case costs. However, the court documents released yesterday, lists the specific description of the group how to curry favor with the doctors and illegal to encourage the use of some drugs (including Weibo Jun (Wellbutrin), paroxetine (Paxil) and Seretide (Advair,)).
Court documents submitted by the U.S. Department of Justice (U.S. Department of Justice) said GlaxoSmithKline “cash bribes disguised as consulting fees, high-priced meals, weekend expenditure on leisure activities and luxury entertainment expenses”. The documents show that, out of Weibo Jun doctors invited to Jamaica to participate in a “training”.
GSK hired radio host, doctors Drew Pinsky (Drew Pinsky) in the radio program “without a trace” to some purpose other than for the Weibo Jun drugs instructions (such as the treatment of erectile dysfunction to help weight loss) to advertise. Only two months of 1999, GSK indirect Lipinski paid $ 275,000.
GlaxoSmithKline to attend the activities organized by their own doctors conducted a survey. The results showed that 12% of the doctors become more willing to open paroxetine for children and young people attending the activities, regulatory agencies and the use of the drug in people under the age of 18 do not allow GSK marketing.
Encourage patients to drugs used for purposes outside the scope of the U.S. Food and Drug Administration (US Food and Drug Administration) approval, GlaxoSmithKline has made considerable short-term sales, but also for a series of rectification actions of regulatory bodies buried under the seed.
Pharmaceutical manufacturers and the behavior of the first decade of this century with the U.S. drug regulatory agencies in the 1990s, reached a series of reconciliation, to pay a fine of increasingly high. GlaxoSmithKline’s payment of a fine is the highest amount ever a. Prior to this, Pfizer (Pfizer) in 2010 paid a fine of $ 2.3 billion, Johnson & Johnson (of Johnson & Johnson) is also involved in the reconciliation of a fine of more than 1 billion U.S. dollars.
GlaxoSmithKline CEO Andrew Vidic, Sir (Sir Andrew Witty) said in a statement: “I want to apologize and reiterate us from mistakes, learned a lesson.”
Processing your request, Please wait....
